Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors
Beria, I., Ballinari, D., Bertrand, J.A., Borghi, D., Bossi, R.T., Brasca, M.G., Cappella, P., Caruso, M., Ceccarelli, W., Ciavolella, A., Cristiani, C., Croci, V., De Ponti, A., Fachin, G., Ferguson, R.D., Lansen, J., Moll, J.K., Pesenti, E., Posteri, H., Perego, R., Rocchetti, M., Storici, P., Volpi, D., Valsasina, B.(2010) J Med Chem 53: 3532-3551
- PubMed: 20397705 
- DOI: 10.1021/jm901713n
- Primary Citation of Related Structures:  
3KB7 - PubMed Abstract: 
Polo-like kinase 1 (Plk1) is a fundamental regulator of mitotic progression whose overexpression is often associated with oncogenesis and therefore is recognized as an attractive therapeutic target in the treatment of proliferative diseases. Here we discuss the structure-activity relationship of the 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline class of compounds that emerged from a high throughput screening (HTS) campaign as potent inhibitors of Plk1 kinase ...